Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus

Table 1 Comparison of efficacy between the two groups, n (%)

Groups	Well-controlled	Effectively-controlled	Ineffective	Overall efficacy
Control group	38	19	3	57 (95.00)
Experimental group	40	18	2	58 (96.67)
χ2				0.349
P value				> 0.05

Table 2 Comparison of levels of bone mineral density and bone metabolic markers between the two groups

Groups	n	BMD, g/cm2		N-MID, ng/mL	β-CTx, pg/mL	25(OH)D, ng/mL
		Lumbar L1-4	Hip
Control group
Before the treatment	60	0.71 ± 0.13	0.62 ± 0.09	19.35 ± 8.14	498.57 ± 210.02	9.54 ± 3.67
After the treatment	60	0.88 ± 0.17a	0.76 ± 0.15a	15.54 ± 5.23	376.27 ± 157.45	17.97 ± 5.74
Experimental group
Before the treatment	60	0.73 ± 0.11	0.64 ± 0.08	20.41 ± 8.13	504.74 ± 237.41	9.23 ± 2.84
After the treatment	60	1.04 ± 0.25ab	0.93 ± 0.20ab	10.68 ± 4.24ab	310.64 ± 146.83ab	25.96 ± 6.91ab

^aP < 0.05 vs before the treatment;

^bP < 0.05 vs the control group after the treatment. 25(OH)D: 25-hydroxyvitamin D; β-CTx: β-isomerized C-terminal telopeptides; BMD: Bone mineral density; N-MID: N-terminal midfragment.